**Tuesday, 29 June 2021**

**15:40-16:00** Opening
- Welcome
- Introduction EBMT and COVID-19 pandemic

  * Rafael de la Cámara (Spain)
  * Nicolaus Kröger (Germany)

**16:00-17:35** The virus
- Mutations, variants and strains. *What do they mean? How do they emerge? What is the situation of the new strains? What implications they have?*
- Diagnostic Toolbox for SARS-CoV-2: *What Works When and Why?*
- Prolonged PCR positivity in HSCT and oncohematologic patients. *How frequent is it? What means?*
- Update on SARS-COV-2 transmission mechanisms
- Live Q&A

  * Chair: D. Navarro
  * Fernando González Candelas (Spain)
  * Hans Hirsch (Switzerland)
  * Fausto Baldanti (Italy)
  * Lidia Morawska (Australia)

**17:35-17:45** Break

**17:45-18:15** Quality in HSCT
- Maintaining quality standards during the COVID-19 pandemic
- Live Q&A

  * Chairs: N. Worel & J. Snowden
  * John Snowden (UK) & Sarah Holtby (UK)

**18:15-18:25** Break

**18:25-19:50** Donors’ standards
- Do we have to test donors for SARS-CoV-2? *When and how?*
- Impact of cryopreservation in HSCT outcome
- Related donors
- Unrelated Donors
- Live Q&A

  * Chairs: N. Worel & J. Snowden
  * Rafael de la Cámara (Spain)
  * Boris Calmels (France)
  * Nina Worel (Austria)
  * Hung Yang (Australia)
### Scientific Programme

**Wednesday, 30 June 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45-17:00</td>
<td><strong>Clinical Impact and management in HSCT patient 1</strong></td>
<td>P. Ljungman &amp; M. Mikulska</td>
<td>Per Ljungman (Sweden), Genovefa Papanicolau (USA), William YK Hwang (Singapore)</td>
</tr>
<tr>
<td></td>
<td>Activity impact and clinical outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• EBMT experience</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Asian Pacific BM Society experience (APBMT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Live Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-17:10</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:10-18:00</td>
<td><strong>Clinical Impact and management in HSCT patient 2</strong></td>
<td>P. Ljungman &amp; M. Mikulska</td>
<td>Akshay Sharma (USA), Roy Chemaly (USA)</td>
</tr>
<tr>
<td></td>
<td>• Other/organ complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Measures to limit SARS-COV-2 nosocomial outbreaks in transplant units</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Live Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00-18:15</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15-19:30</td>
<td><strong>Clinical Impact and management in HSCT patient 3</strong></td>
<td>J. Styczynski &amp; R. de la Cámara</td>
<td>Dina Averbuch (Israel), José Luis Piñana (Spain), Carolina Garcia-Vidal (Spain)</td>
</tr>
<tr>
<td></td>
<td>• COVID-19 in HSCT paediatric patients. <em>It is really a low frequency and benign disease?</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Epidemiology of other common seasonal respiratory viruses in HSCT during SARS-COV-2 pandemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fungal and bacterial superinfections in COVID patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Live Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30-19:40</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:40-20:30</td>
<td><strong>Clinical Impact and management in HSCT patient 4</strong></td>
<td>J. Styczynski &amp; R. de la Cámara</td>
<td>Malgorzata Mikulska (Italy), Ellie Azoulay (France)</td>
</tr>
<tr>
<td></td>
<td>Updated in COVID-19 therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Antivirals, convalescent plasma, immunomodulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Oxygen support, Ventilation, anticoagulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Live Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ALL SCHEDULES ARE BASED ON CENTRAL EUROPEAN SUMMER TIME*
Thursday, 1 July 2021

15:00-15:45  Industry Symposium Organised and funded by Jazz Pharmaceuticals
Tackling the challenge of HSCT and hepatic VOD through COVID-19: a case-based approach

- Welcome and introduction
- Paediatric perspective: overcoming the challenges of severe hepatic VOD during the pandemic
- Adult perspective: overcoming the challenges of severe hepatic VOD during the pandemic
- Live Q&A, summary and close

Chair: R. Duarte (Spain)
Selim Corbacioglu (Germany)
Rafael Duarte (Spain)

15:45-16:50  Nursing and patients’ perspective

- Nursing HSCT in COVID pandemic
- PPE and the difficulties of isolation/protective environment
- Patients’ perspective
- Live Q&A

Chair: J. Murray
Michelle Kenyon (UK)
Iris Agreiter (Ireland)
Natacha Bolaños (Spain)

16:50-17:10  Break

17:10-18:30  Immune response and prevention 1

How is the immune response to SARS-CoV-2?

- General aspects
  How to measure T and B cell response against SARS-COV-2.
  Duration of the immune response
  Protective immunity: can we define it?
- Antibody and B cell responses to COVID-19 disease and vaccination
- Specific aspects of immune response to SARS-CoV-2 in HSCT
- Live Q&A

Chair: C. Cordonnier & D. Averbuch
Hans-Gustaf Ljunggren (Sweden)
Karin Loré (Sweden)
Michael Boeck (US)

18:30-18:40  Break

18:40-19:10  Immune response and prevention 2

Vaccines
- Type of vaccines
- Experiences in immunosuppressed /HSCT patients
- Recommendations
- Live Q&A

Chair: D. Averbuch
Catherine Cordonnier (France)

19:10-19:15  Closing Remarks

Nicolaus Kröger